BioCryst Pharmaceuticals 将来の成長

Future 基準チェック /46

BioCryst Pharmaceuticalsは、72.8%と15.3%でそれぞれ年率72.8%で利益と収益が成長すると予測される一方、EPSはgrowで72.8%年率。

主要情報

72.8%

収益成長率

72.8%

EPS成長率

Biotechs 収益成長	28.4%
収益成長率	15.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	19 Nov 2024

今後の成長に関する最新情報

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08

Recent updates

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

Sep 29

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

May 07

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

Apr 29

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Feb 27

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jan 09

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

Jun 08

BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks

Aug 18

BioCryst Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

BioCryst Pharmaceuticals: Waiting For Clarity

Jul 25

BioCryst: A Prudent Diversification

Jun 24

業績と収益の成長予測

NasdaqGS:BCRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	625	74	170	N/A	8
12/31/2025	534	-14	93	46	10
12/31/2024	446	-78	5	-52	9
9/30/2024	413	-124	-57	-56	N/A
6/30/2024	382	-146	-86	-84	N/A
3/31/2024	355	-209	-104	-101	N/A
12/31/2023	331	-227	-97	-95	N/A
9/30/2023	318	-236	-112	-110	N/A
6/30/2023	307	-243	-124	-123	N/A
3/31/2023	290	-226	-133	-132	N/A
12/31/2022	271	-247	-163	-162	N/A
9/30/2022	238	-193	-172	-170	N/A
6/30/2022	204	-210	-163	-161	N/A
3/31/2022	188	-194	-162	-159	N/A
12/31/2021	157	-184	-145	-142	N/A
9/30/2021	114	-227	-154	-152	N/A
6/30/2021	79	-214	-168	-167	N/A
3/31/2021	32	-209	-173	-173	N/A
12/31/2020	18	-183	-136	-135	N/A
9/30/2020	54	-125	-103	-103	N/A
6/30/2020	49	-116	-93	-92	N/A
3/31/2020	48	-115	-86	-86	N/A
12/31/2019	49	-109	-90	-90	N/A
9/30/2019	12	-134	-103	-103	N/A
6/30/2019	12	-126	-111	-111	N/A
3/31/2019	23	-107	-100	-100	N/A
12/31/2018	21	-101	-93	-93	N/A
9/30/2018	22	-93	-79	-79	N/A
6/30/2018	29	-79	N/A	-56	N/A
3/31/2018	20	-77	N/A	-52	N/A
12/31/2017	25	-66	N/A	-41	N/A
9/30/2017	30	-51	N/A	-36	N/A
6/30/2017	29	-47	N/A	-42	N/A
3/31/2017	31	-47	N/A	-43	N/A
12/31/2016	26	-55	N/A	-53	N/A
9/30/2016	22	-69	N/A	-62	N/A
6/30/2016	25	-72	N/A	-58	N/A
3/31/2016	46	-51	N/A	-28	N/A
12/31/2015	48	-43	N/A	-13	N/A
9/30/2015	49	-37	N/A	-12	N/A
6/30/2015	41	-31	N/A	-8	N/A
3/31/2015	17	-50	N/A	-33	N/A
12/31/2014	14	-45	N/A	-39	N/A
9/30/2014	19	-39	N/A	-29	N/A
6/30/2014	18	-38	N/A	-28	N/A
3/31/2014	17	-36	N/A	-24	N/A
12/31/2013	17	-30	N/A	-27	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BCRXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: BCRX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: BCRX今後 3 年以内に収益を上げることが予想されます。

収益対市場: BCRXの収益 ( 15.3% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: BCRXの収益 ( 15.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BCRXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

BioCryst Pharmaceuticals 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 14%

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026

Consensus estimates of losses per share improve by 41%

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Recent updates

BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland

Consensus estimates of losses per share improve by 14%

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Insufficient new directors

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

Consensus estimates of losses per share improve by 41%

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Senior VP recently bought US$202k worth of stock

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Consensus EPS estimates upgraded to US$0.60 loss

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Price target decreased by 13% to US$12.20

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Full year 2023 earnings: EPS misses analyst expectations

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Forecast breakeven date pushed back to 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

Price target decreased by 7.3% to US$14.09

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

New minor risk - Shareholder dilution

No longer forecast to breakeven

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.23 loss in 3Q 2022)

No longer forecast to breakeven

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Consensus EPS estimates fall by 16%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CEO, President & Executive Director exercised options to buy US$264k worth of stock.

Consensus EPS estimates fall by 13%

Price target decreased by 7.5% to US$15.45

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

CEO, President & Executive Director exercised options and sold US$493k worth of stock

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

Forecast to breakeven in 2025

CEO, President & Executive Director exercised options and sold US$3.4m worth of stock